Cytochromes P450 and ischemic heart injury: Potential role for inhibitors in the treatment of myocardial infarction

Drug Discovery Today: Disease Mechanisms

Volumn 2, Issue 1, 2005, Pages 123-127

  Granville, David J ^a   Gottlieb, Roberta A ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 OCTADECYNOIC ACID; 20 HYDROXYICOSATETRAENOIC ACID; ADENOSINE TRIPHOSPHATE; ALKANE 1 MONOOXYGENASE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ARACHIDONIC ACID; CANDESARTAN; CHLORAMPHENICOL; CIMETIDINE; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 INHIBITOR; ENZYME INHIBITOR; GLIBENCLAMIDE; MICONAZOLE; MITOGEN ACTIVATED PROTEIN KINASE; N METHYLSULFONYL 12,12 DIBROMODODEC 11 ENAMIDE; N METHYLSULFONYL 6 (2 PROPARGLYLOXYPHENYL)HEXANAMIDE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SULFAPHENAZOLE; UNCLASSIFIED DRUG;

ARACHIDONIC ACID METABOLISM; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CORONARY ARTERY DILATATION; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SYNTHESIS; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION;

EID: 33645047904     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2005.05.005     Document Type: Review

References (22)

1. A.L. Hunter et. al. Cytochrome p450 enzymes and cardiovascular disease Can. J. Physiol. Pharmacol. 82 2004 1053-1060
2. E.T. Morgan et. al. Mechanisms of cytochrome P450 regulation by inflammatory mediators Toxicology 181-182 2002 207-210
3. E.T. Morgan et. al. Physiological and pathophysiological regulation of cytochrome P450 Drug Metab. Dispos. 26 1998 1232-1240
4. X. Ding et. al. Human extrahepatic cytochromes P450: Function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts Annu. Rev. Pharmacol. Toxicol. 43 2003 149-173
5. K.R. Chien et. al. Accumulation of unesterified arachidonic acid in ischemic canine myocardium. Relationship to a phosphatidylcholine deacylation-reacylation cycle and the depletion of membrane phospholipids Circ. Res. 54 1984 313-322
6. I. Fleming Cytochrome p450 and vascular homeostasis Circ. Res. 89 2001 753-762
7. W.B. Campbell et. al. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors Circ. Res. 78 1996 415-423
8. P.F. Pratt et. al. 20-HETE relaxes bovine coronary arteries through the release of prostacyclin Hypertension 31 1998 237-241
9. Y.H. Ma et. al. 20-Hydroxyeicosatetraenoic acid is an endogenous vasoconstrictor of canine renal arcuate arteries Circ. Res. 72 1993 126-136
10. V. Randriamboavonjy et. al. 20-HETE-induced contraction of small coronary arteries depends on the activation of Rho-kinase Hypertension 41 2003 801-806
11. K. Nithipatikom et. al. Determination of cytochrome P450 metabolites of arachidonic acid in coronary venous plasma during ischemia and reperfusion in dogs Anal. Biochem. 292 2001 115-124
12. K. Nithipatikom et. al. Inhibition of cytochrome P450 omega-hydroxylase: a novel endogenous cardioprotective pathway Circ. Res. 95 2004 e65-e71
13. E.R. Gross et. al. Cytochrome P450 omega-hydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel J. Mol. Cell. Cardiol. 37 2004 1245-1249
14. V. Randriamboavonjy et. al. The synthesis of 20-HETE in small porcine coronary arteries antagonizes EDHF-mediated relaxation Cardiovasc. Res. 65 2005 487-494
15. M. Shimizu et. al. The angiotensin II AT1-receptor antagonist candesartan improves functional recovery and reduces the no-reflow area in reperfused ischemic rat hearts J. Cardiovasc. Pharmacol. 34 1999 78-81
16. S. Wu et. al. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart J. Biol. Chem. 271 1996 3460-3468
17. J. Seubert et. al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway Circ. Res. 95 2004 506-514
18. Y.F. Xiao et. al. Enhancement of cardiac L-type Ca2+ currents in transgenic mice with cardiac-specific overexpression of CYP2J2 Mol. Pharmacol. 66 2004 1607-1616
19. S.C. Bondy et. al. Contribution of hepatic cytochrome P450 systems to the generation of reactive oxygen species Biochem. Pharmacol. 48 1994 155-159
20. D.J. Granville et. al. Reduction of ischemia and reperfusion-induced myocardial damage by cytochrome P450 inhibitors Proc. Natl. Acad. Sci. USA 101 2004 1321-1326
21. S. Fichtlscherer et. al. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease Circulation 109 2004 178-183
22. I. Fleming et. al. Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries Circ. Res. 88 2001 44-51